MEDIA RELEASE

Molecular Partners Publishes Audited Financial Results and Annual Report 2017

Zurich-Schlieren, March 16, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today published its audited Financial Results for 2017 and the company's 2017 Annual Report.

The audited Financial Results for 2017 and the company's 2017 Annual Report are available on the investors section of the company' website.

Financial Calendar

April 18, 2018

Annual General Meeting

April 26, 2018

Q1 2018 Management Statement

August 30, 2018

Publication of 2018 Half-year Results

November 01, 2018

Q3 2018 Management Statement

http://investors.molecularpartners.com/financial-calendar-and-events/

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies. With a management team that includes many of the founding scientists, the company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.

For further details, please contact:

Patrick Amstutz, CEO

Andreas Emmenegger, CFO

patrick.amstutz@molecularpartners.com

andreas.emmenegger@molecularpartners.com

Tel: +41 44 755 77 00

Tel: +41 44 755 77 00

Rolf Schläpfer

Susan A. Noonan

Hirzel.Neef.Schmid.Counselors

S.A. Noonan Communications, LLC

rolf.schlaepfer@konsulenten.ch

susan@sanoonan.com

Tel: +41 43 344 42 42

Tel.: +1 212 966 3650

*DARPin® is a registered trademark owned by Molecular Partners AG

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.


Media Release (PDF)



Provider
 Channel
 Contact
EQS Group Ltd., Switzerland
www.tensid.ch


 newsbox.ch
www.newsbox.ch


 Provider/Channel related enquiries
cs.switzerland@eqs.com
+41 41 763 00 50